08

Feb2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of January 31, 2018: 35 negotiations are currently underway with 2 new files added since the last update of December 31, 2017: Spinraza (nusinersen): Used to treat 5q Spinal Muscular Atrophy Victoza (liraglutide): Used ... Read More

07

Dec2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of November 30, 2017: 39 negotiations are currently underway with 4 new files added since the last update of October 31, 2017: Cerdelga (eliglustat): Used to treat Gaucher disease Cerezyme (imiglucerase): Used to treat ... Read More

08

Nov2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017: 46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017: Gazyva (obinutuzumab): Used to treat follicular lymphoma Lynparza (olaparib): Used to treat ... Read More

11

Oct2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:  51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017: Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery) Glatect ... Read More

11

Sep2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:        47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017: Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history ... Read More

09

Aug2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2017:  46 negotiations are currently underway with 7 new files added since the last update of June 30, 2017: Cinqair (reslizumab): Used to treat severe eosinophilic asthma Giotrif (afatinib): Used to ... Read More

11

Jul2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017: 42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017: Caprelsa (vandetanib): Used to treat medullary thyroid cancer Kyprolis (carfilzomib): Used to ... Read More

15

Jun2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017: 43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017: Brivlera (brivarcetam): Used to treat partial-onset seizures Butrans (buprenorphine): Used to treat ... Read More

16

May2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017: 38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017: Cosentyx (secukinumab): Use to treat psoriatic arthritis Cosentyx (secukinumab): Used to treat ... Read More

13

Apr2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017: 30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017: Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma Campral ... Read More